The US Food and Drug Administration (FDA) has approved medical device company Neuspera Medical’s next-generation ultra-miniaturised system for peripheral nerve stimulation.
The leadless micro-implant is designed for chronic peripheral nerve pain management. It offers neurostimulation therapy through a wireless platform, powered by a wearable transmitter.
The system also includes a smartphone app and an iPad-based clinician programmer which provides physicians with a command centre view of implanted devices and external wireless transmitters.
